肝硬化并门静脉血栓脂代谢相关差异蛋白的研究

摘要/Abstract

摘要： 目的筛选肝硬化合并门静脉血栓(Portal vein thrombosis,PVT)患者的血清差异表达蛋白,对脂代谢相关差异表达蛋白进行分析。方法收集2015年11月至2016年11月在新疆医科大学第一附属医院感染疾病中心诊治的肝硬化合并PVT患者的血清标本22份,肝硬化未合并PVT患者的血清标本23份。采用相对和绝对同位素定量标记(isobaric tags for relative and absolute quantification,iTRAQ)联合色谱质谱技术筛选两组间的血清差异表达蛋白,对脂代谢相关差异表达蛋白进行生物信息学分析。结果两组间共检测出800个蛋白,与脂肪代谢相关的蛋白共有17个,其中7个蛋白在两组间有差异,3个差异表达蛋白(APOA1,FABP1,APOB)在脂肪消化和吸收通路中显著富集。结论 APOA1、FABP1、APOB可能为肝硬化发生PVT的潜在生物标志物,值得进一步研究。

关键词: 肝硬化, 门静脉血栓, APOA1, FABP1, APOB

熊静平, 范晓棠, 张跃新. 肝硬化并门静脉血栓脂代谢相关差异蛋白的研究[J]. 肝脏, 2019, 24(6): 645-648.

参考文献

[1] Handa P, Crowther M, Douketis JD. Portal vein thrombosis:a Clinician-Oriented and practical review.Clin Appl Thromb Hemost, 2014, 20:498-506.
[2] 陈锋,熊吉信,唐新华.血脂水平与静脉血栓形成关系的Meta分析.军医进修学院学报,2009,30:476-478.
[3] Yang L, Rudser KD, Higgins L, et al. Novel biomarker candidates to predict hepatic fibrosis in hepatitis C identified by serum proteomics.Dis Sci,2011, 56:3305-3315.
[4] Kolla V, Jeno P, Moes S, et al. Quantitative proteomics analysis ofmAternal plasma in Down syndrome pregnancies using isobaric tagging reagent(iTRAQ).J Biomed Biotechnol, 2010, 2010:952047.
[5] 中华医学会肝病学分会,中华医学会感染病学分会慢性乙型肝炎防治指南(2015更新版).中华肝脏病杂志,2015,23:888-905.
[6] Applied BiosystemsiTRAQ^TM Reagents Amine-Modifying Labeling Reagents for Multiplexed Relative and Absolute Protein. Applied Biosystems, 2004.
[7] Moriya Y, Itoh M, Okuda S, et al. KAAS: an automatic genome annotation and pathway reconstruction server. Nucleic Acids Res,35, 2007:W182-185.
[8] Guo L,Ai J,Zheng Z,et al. High density lipoprotein protects against polymicrobe-induced sepsis in mice.J Biol Chem, 2013,288:17947-17953.
[9] Frances chini G. Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease.Am J Cardiol, 2001, 88:9N-13N.
[10] Burger D. Cell contact-mediated signaling of monocytes by stimulated T cells:amAjor pathway for cytokine induction.Eur Cytokine Netw, 2000, 11:346-353.
[11] 叶文桃,周宇,麦海妍.肝硬化患者肝功能与脂蛋白和载脂蛋白相关性分析实用医学杂志,2001,17:291-292.
[12] Mahfouz MM,Kummerow FA. Oxysterols and TBARS are among the LDL oxidation products which enhance thromboxane A2 synthesis by platelets. Prostaglandins Other Lipid Mediat,1998,56:197-217.
[13] Morelli VM,Lijfering WM, Bos MHA,et al.Lipid levels and risk of venous thrombosis: results from the MEGA-study.Eur J Epidemiol, 2017,32:669-681.
[14] Wolfrum C, Borrmanncm, Borchers T, et al. Fatty acids and hypolipidemic drugsregulate peroxisome proliferator-activated receptors alpha and gamma- mediated gene expression via liver fatty acid binding protein:a signaling path to the nucleus.Proc Natl Acad Sci U S A, 2001, 98:2323-2328.
[15] Wang G, Gong Y, Anderson J, et al. Antioxidative function of L-FABP in L-FABP stably transfected Chang liver cells.Hepatology,2005,42:871-879.
[16] Kamijo A, Sugaya T, Hikawa T, et al. Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease.Mol Cell Biochem, 2006, 284:175-182.
[17] Chiodini BD,Barlera S, Franzosimg,et al.APOB gene polymorphisms and coronary artery disease:a meta-analysis.Atherosclerosis,2003,167:355-366.